Zobrazeno 1 - 10
of 39
pro vyhledávání: '"David D. Hirsh"'
Publikováno v:
Archives of Physical Medicine and Rehabilitation. 79:306-312
To determine which nerve conduction parameters can predict the presence of acute denervation in carpal tunnel syndrome.The electrodiagnostic laboratories of a hospital and a county hospital district.A retrospective review.A total of 1,590 consecutive
Autor:
Jonathan R. Strayer, Faye Y. Chiou-Tan, David D. Hirsh, Stephen M. Tuel, Jane C. Johnson, Michael M. Priebe
Publikováno v:
American Journal of Physical Medicine & Rehabilitation. 75:84-87
Severe pain occurs in 5-30% of the spinal cord-injured (SCI) population and is difficult to treat. Subarachnoid lidocaine has been used in selected patients with some success. Mexiletine, an analog of lidocaine that acts at Na+/K+ channels in the per
Autor:
David D. Hirsh
Publikováno v:
Archives of Physical Medicine and Rehabilitation. 75:1049-1050
Publikováno v:
American Journal of Physical Medicine & Rehabilitation. 77:174
Publikováno v:
American Journal of Physical Medicine & Rehabilitation. 74:178
Autor:
William L. Doss, David D. Hirsh
Publikováno v:
Archives of Physical Medicine and Rehabilitation. 75:1059
Publikováno v:
JAMA: The Journal of the American Medical Association. 242:340
A study was undertaken to determine whether use of a condom catheter collection system (CCCS) is associated with urinary tract infection (UTI). No UTI developed in 79 episodes of CCCS use in patients who were cooperative or because of paralysis were
Autor:
Webb K; Centre for Medical Education, School of Medicine, Cardiff University, Cardiff, UK., Williams F; Swansea University, Swansea, UK., Riley S; College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK., Hirsh D; Harvard Medical School, Cambridge Health Alliance, Cambridge, MA, USA.
Publikováno v:
BMJ (Clinical research ed.) [BMJ] 2024 Mar 26; Vol. 384, pp. q710. Date of Electronic Publication: 2024 Mar 26.
Autor:
Trenkenschuh E; Pharmaceutical Development, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach/Riß, Germany., Blattner SM; Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach/Riß, Germany., Hirsh D; Material and Analytical Sciences, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, United States., Hoffmann R; Pharmaceutical Development, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach/Riß, Germany., Luebbert C; amofor GmbH, Otto-Hahn-Straße 15, 44227 Dortmund, Germany., Schaefer K; Pharmaceutical Development, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach/Riß, Germany.
Publikováno v:
Molecular pharmaceutics [Mol Pharm] 2024 Mar 04; Vol. 21 (3), pp. 1309-1320. Date of Electronic Publication: 2024 Feb 12.
Autor:
Allington D; King's College London, London, UK. daniel.allington@kcl.ac.uk., Hirsh D; Goldsmiths, University of London, London, UK., Katz L; Xenophon College, London, UK.
Publikováno v:
Scientific reports [Sci Rep] 2023 Dec 05; Vol. 13 (1), pp. 21104. Date of Electronic Publication: 2023 Dec 05.